SGLT2 Inhibitors vs GLP-1 Drugs: Head-to-Head Comparison for Heart Events | Research

The takeaway

Meta-analysis comparing SGLT2 inhibitors and GLP-1 receptor agonists for major adverse cardiovascular events finds both effective, with subtle differences in specific outcome profiles.

Complementary, not competing
GLP-1 drugs better for atherosclerotic events, SGLT2 better for heart failure — supporting combination therapy

What the researchers found

Both SGLT2 inhibitors and GLP-1 drugs reduce MACE, but with different strengths: SGLT2 for heart failure/kidney, GLP-1 for atherosclerotic events.

Why it matters

Clinicians need to choose between or combine these two powerful drug classes. Understanding their complementary cardiovascular profiles enables personalized treatment.

The numbers in context

Compared SGLT2 inhibitors vs. GLP-1 RAs for MACE outcomes. Multiple RCTs included.

How the study worked

Systematic review and meta-analysis comparing SGLT2 inhibitors and GLP-1 RA cardiovascular outcomes from randomized trials.

Who was studied

Adults with type 2 diabetes at cardiovascular risk across randomized controlled trials

What this study cannot tell us

Indirect comparison from separate trials. Different trial populations and designs. Head-to-head cardiovascular outcome trials between the two classes do not exist.

How to read the evidence

Strong evidence: meta-analysis of major cardiovascular outcome trials, though indirect comparison has limitations.

When this study was published

Published in 2025. Most comprehensive SGLT2 vs GLP-1 cardiovascular comparison.

The bigger picture

Rather than competing, SGLT2 and GLP-1 drugs complement each other. Their different cardiovascular strengths support combination therapy — SGLT2 for heart failure/kidney protection plus GLP-1 for anti-atherosclerotic benefits.

Questions still open

Should high-risk patients receive both SGLT2 and GLP-1 drugs?
Which class should be started first?
Do combined SGLT2+GLP-1 cardiovascular benefits add up as expected?

Common questions

Which is better: SGLT2 or GLP-1 drugs?

Neither is universally better — they have complementary strengths. GLP-1 drugs are stronger at preventing heart attacks and strokes. SGLT2 drugs are stronger at preventing heart failure and protecting kidneys. Many patients may benefit from taking both.

Can I take both SGLT2 and GLP-1 drugs?

Yes — combining them is increasingly common and supported by their complementary cardiovascular profiles. Together they provide broader protection than either alone. Discuss with your doctor.

Read the original research

SGLT2 inhibitors versus GLP-1 receptor agonists for major adverse cardiovascular events in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.

BMC cardiovascular disorders, 26(1), 88

View on PubMed ↗Publisher’s paper ↗

Citation

Ahmed, Ali Abdelhaleem Omar; Ahmed, Omer Abdalhaleem Omer; Ahmed, Reem Abdelhaleem Omar; Ahmed, Rana Abdelhaleem Omar; Mohammed, Mawahib Ahmed Eltayeb Abdullah; Ahmed, Yara; Abbas, Mahmood; Ibrahim, Mamdoh Abbas Ali; Abakar, Mugtaba Eltag Mohammed; Dahab, Kamal Eldeen M; Elbashir, Roaa Mohamed Ali; Mohamed, Khalid H; Mansour, Maram Adil. (2025). SGLT2 inhibitors versus GLP-1 receptor agonists for major adverse cardiovascular events in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.. BMC cardiovascular disorders, 26(1), 88. https://doi.org/10.1186/s12872-025-05455-4